Assets
Create Platinum Slide Series
8 slides in article Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis
Viewing slides 7-8 of 8
- S0302-2838(08)01212-8.results drag remove slide Results • We identified 12 cases (5 complete responses with sunitinib, 1 complete response with sorafenib and 6 partial responses with sunitinib followed by complete metastasectomy of residual ... • We identified 12 cases (5 complete responses with sunitinib, 1 complete response with ... Zoom
- S0302-2838(08)01212-8.conclusion drag remove slide Conclusion • Discontinuation of treatment and readministration in case of recurrence may be feasible for selected patients with mRCC who achieve a complete response under TKI treatment with or without ... • Discontinuation of treatment and readministration in case of recurrence may be feasible for ... Zoom
Viewing slides 7-8 of 8
Copyright © 